Zenosense, Inc.: MIDS Quantitative Testing Commences

Press release Feb 22, 2017 OTC Disclosure & News Service Zenosense, Inc.: MIDS Quantitative Testing Commences VALENCIA, SPAIN–(Marketwired – Feb 22, 2017) – Zenosense, Inc. (OTCQB: ZENO) (“Zenosense”, the “Company”), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care (“POC”) handheld device for the early detection…